|1.||Saini, Manpreet Kaur: 1 article (06/2014)|
|2.||Sanyal, Sankar Nath: 1 article (06/2014)|
|3.||Sousa, Célia: 1 article (08/2008)|
|4.||Nunes, Cláudia: 1 article (08/2008)|
|5.||Lúcio, Marlene: 1 article (08/2008)|
|6.||Tavares, Joana: 1 article (08/2008)|
|7.||Cordeiro-da-Silva, Anabela: 1 article (08/2008)|
|8.||Ferreira, Helena: 1 article (08/2008)|
|9.||Reis, Salette: 1 article (08/2008)|
|10.||Lima, José L F C: 1 article (08/2008)|
02/01/1981 - "Prior studies of fluorescence anisotropy (polarization) with diphenylhexatriene in normal and malignant cell populations have shown differences which have been attributed to an altered membrane lipid composition in cancer. "
04/09/1990 - "Plasma membranes of metastatic cells were more fluid (lower limiting anisotropy) than those of local tumor cells as indicated by multifrequency phase and modulation fluorometry and the fluorescence probe molecule, 1,6-diphenyl-1,3,5-hexatriene. "
01/01/1987 - "The fluorescence of intensivity of membrane-bound diphenylhexatriene (DFHT) of erythrocytes of the cancer patients is found to increase as compared to that of donors. "
01/05/1983 - "86, 1063-1068) indicated us that the active tumor promoter TPA (12-O-tetradecanoylphorbol 13-acetate) decreased fluorescence polarisation of diphenylhexatriene in lymphoblastoid and rat embryo cells. "
02/01/1981 - "We conclude that alterations in membrane lipid fluidity, as measured by the diphenylhexatriene probe, are not consistently found in lymphoid neoplasms and hence cannot presently be invoked to account for the malignant behavior of these cells. "
|2.||Alzheimer Disease (Alzheimer's Disease)
07/01/1999 - "Previous fluorescence studies employing 1,6-diphenyl-1,3,5-hexatriene (DPH) have revealed an increase in the fluidity of platelet membranes from individuals with Alzheimer's disease (AD) and their first-degree relatives. "
03/01/1992 - "To test whether increased platelet membrane fluidity as measured by decreased steady state fluorescence anisotropy (rs) of diphenylhexatriene is a biologic/diagnostic marker for Alzheimer's disease (AD), we enrolled 95 clinically diagnosed, probable AD cases from our Alzheimer's Disease Patient Registry and 133 control subjects of similar age and sex randomly selected from the same population base as the cases. "
01/01/1990 - "Increased platelet membrane fluidity, as determined by the fluorescence anisotropy of 1,6-diphenyl-1,3,5-hexatriene (DPH), appears to be a stable, inherited trait that identifies a prominent subgroup of patients with Alzheimer's disease with distinct clinical features. "
06/01/1989 - "The fluorescence anisotropy of 1,6-diphenyl-1,3,5-hexatriene in labeled platelet membranes, an index of membrane fluidity, is a stable, familial trait that is associated with a clinically distinct subtype of Alzheimer disease. "
10/23/1987 - "The fluorescence anisotropy of 1,6-diphenyl-1,3,5-hexatriene in labeled platelet membranes, an index of membrane fluidity, identifies a prominent subgroup of patients with Alzheimer's disease who manifest distinct clinical features. "
07/01/1976 - "The microviscosity of the hydrophobic region of the membrane of infectious hematopoietic necrosis virus was determined using fluorescence depolarization analysis of the probe 1,6-diphenyl-1,3,5-hexatriene and was found to be much lower at 37 C than that of another rhabdovirus, vesicular stomatitis virus. "
08/10/1976 - "The fluorescence probe 1,6-diphenyl-1,3,5-hexatriene was used to study and compare the dynamic properties of the hydrophobic region of vesicular stomatitis virus grown on L-929 cells, plasma membrane of L-929 cells prepared by two different methods, liposomes prepared from virus lipids and plasma membrane lipids, and intact L-929 cells. "
06/01/1988 - "Fluorescence polarisation of 1,6-diphenyl-1,3,5-hexatriene was used to study the lymphocyte membrane in rheumatoid arthritis. "
01/01/1989 - "We have demonstrated significant differences in 1,6-diphenyl-1,3,5-hexatriene fluorescence polarization values between lymphocyte membranes of untreated rheumatoid arthritis patients and lymphocyte membranes of patients treated with antirheumatic drugs, such as hydroxychloroquine and auranofin. "
|1.||Fluorescent Dyes (Fluorescent Probes)
|6.||1- (4- (trimethylamino)phenyl)- 6- phenylhexa- 1,3,5- triene
|8.||Antirheumatic Agents (DMARD)
|10.||Membrane Proteins (Integral Membrane Proteins)